| Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. | |
| | |
MedLine Citation:
|
PMID: 11583728 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cilostazol, a novel oral phosphodiesterase inhibitor, has shown consistent improvement in exercise tolerance in patients with intermittent claudication (IC). In addition to this effect, cilostazol has previously been shown to have beneficial effects on the dyslipidemia, i.e., combination of high triglycerides with low high-density-lipoprotein cholesterol (HDL-C) levels. Interleukin-6 (IL-6) suppresses the activity of lipoprotein lipase, which modulates the metabolism of triglycerides and HDL-C. To determine whether a reduction of IL-6 contributes to the improvement of lipid profiles, we prospectively investigated the effect of cilostazol (n=16, 100 mg, twice daily) on the changes of lipid profiles and on the association with the changes of IL-6 compared with those of pentoxifylline (n=16, 400 mg, bid) in patients with IC. After eight weeks of administration of cilostazol to patients with IC, walking distances were increased, associated with a 29% decrease in plasma triglycerides and a 13% increase in HDL-C. No significant changes of lipid profiles in the pentoxifylline and placebo groups were observed although a similar improvement in walking distances was achieved in the pentoxifylline group. IL-6 levels were significantly reduced in patients receiving cilostazol as compared with those receiving placebo or pentoxifylline. The cilostazol-induced changes in the IL-6 were positively related to those of triglycerides in the cilostazol group (r=0.63, P<0.05) and negatively related to those of HDL-C (r=-0.55, P<0.05). These findings suggest that in addition to consistent improvement of exercise tolerance, cilostazol may improve lipid profiles by reducing IL-6 release. However, pentoxifylline did not affect lipid profiles although a similar improvement of maximal walking distance (MWD) was achieved. |
| | |
Authors:
|
T M Lee; S F Su; J J Hwang; C D Tseng; M F Chen; Y T Lee; S S Wang |
Related Documents
:
|
18784538 - Changing clinical profile of patients entering cardiac rehabilitation/secondary prevent... 12241128 - Oxidation injury in patients receiving hmg-coa reductase inhibitors: occurrence in pati... 17598368 - Beneficial effect of low-density lipoprotein apheresis (ldl-a) on refractory nephrotic ... 7830728 - Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patie... 17453148 - Discovery of serum biomarkers in astrocytoma by seldi-tof ms and proteinchip technology. 9972768 - Anesthesia for intranasal surgery: a comparison between tracheal intubation and the fle... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Atherosclerosis Volume: 158 ISSN: 0021-9150 ISO Abbreviation: Atherosclerosis Publication Date: 2001 Oct |
Date Detail:
|
Created Date: 2001-10-03 Completed Date: 2002-01-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0242543 Medline TA: Atherosclerosis Country: Ireland |
Other Details:
|
Languages: eng Pagination: 471-6 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Cardiology Section, National Taiwan University Hospital, 7, Chung-Shan S. RD., Taipei, 10002, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antilipemic Agents / therapeutic use* Cholesterol / blood Cholesterol, HDL / blood Cholesterol, LDL / blood Double-Blind Method Enzyme Inhibitors / therapeutic use* Female Humans Interleukin-6 / blood*, physiology Intermittent Claudication / blood*, drug therapy Lipids / blood* Male Pentoxifylline / therapeutic use* Phosphodiesterase Inhibitors / therapeutic use* Prospective Studies Tetrazoles / therapeutic use* Triglycerides / blood Vasodilator Agents / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Enzyme Inhibitors; 0/Interleukin-6; 0/Lipids; 0/Phosphodiesterase Inhibitors; 0/Tetrazoles; 0/Triglycerides; 0/Vasodilator Agents; 57-88-5/Cholesterol; 6493-05-6/Pentoxifylline; 73963-72-1/cilostazol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship between response of gamma-glutamyl transpeptidase to alcohol drinking and risk factors ...
Next Document: Increased leukocyte activity as a predictor for flow-limiting coronary lesions in patients with angi...